Carisma Therapeutics (CARM) Institutional Ownership $0.40 -0.01 (-1.99%) Closing price 04:00 PM EasternExtended Trading$0.40 +0.01 (+1.27%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Carisma Therapeutics (NASDAQ:CARM)CurrentInstitutional OwnershipPercentage44.27%Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$1.24MNumber ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$1.09M Get CARM Insider Trade Alerts Want to know when executives and insiders are buying or selling Carisma Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CARM Institutional Buying and Selling by Quarter Carisma Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/6/2025Universal Beteiligungs und Servicegesellschaft mbH200,000$62K0.0%N/A0.479% 2/17/2025Millennium Management LLC120,157$50K0.0%-15.7%0.288% 2/13/2025Renaissance Technologies LLC231,357$97K0.0%+11.9%0.554% 11/19/2024Barclays PLC549,305$539K0.0%+3,661,933.3%1.316% 11/16/2024Geode Capital Management LLC259,184$254K0.0%-8.5%0.621% 11/15/2024Barclays PLC549,305$539K0.0%+3,661,933.3%1.316% 11/15/2024Wexford Capital LP34,861$34K0.0%+75.5%0.083% 9/16/2024Point72 Asia Singapore Pte. Ltd.26,006$40K0.0%N/A0.063% 8/15/2024Point72 Asia Singapore Pte. Ltd.26,006$40K0.0%N/A0.063% 8/15/2024TPG GP A LLC842,031$1.28M0.0%-42.0%2.027% Get the Latest News and Ratings for CARM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/9/2024Renaissance Technologies LLC139,360$212K0.0%-38.3%0.335% 5/10/2024Vanguard Group Inc.1,579,961$3.59M0.0%+0.7%3.803% 5/7/2024Empowered Funds LLC26,984$61K0.0%-43.9%0.065% 2/14/2024Trustees of The University of Pennsylvania1,252,107$3.67M10.3%-28.9%3.102% 10/13/2023SG Americas Securities LLC13,653$58K0.0%N/A0.034% 9/21/2023Barclays PLC5,312$47K0.0%N/A0.013% 8/4/2023American International Group Inc.12,834$113K0.0%N/A0.032% 7/27/2023EA Series Trust40,434$355K0.0%N/A0.100% 6/15/2023Trustees of The University of Pennsylvania2,182,812$6.77M6.6%N/A5.422% 5/15/2023Wittenberg Investment Management Inc.46,703$145K0.1%N/A0.459% 5/12/2023Deuterium Capital Management LLC51,256$159K0.2%N/A0.504% 5/10/2023Connor Clark & Lunn Investment Management Ltd.14,796$46K0.0%N/A0.145% 5/3/2023Jump Financial LLC17,542$54K0.0%N/A0.172% 5/1/2023Virtu Financial LLC15,335$48K0.0%N/A0.151% 4/27/2023Stratos Wealth Partners LTD.19,899$62K0.0%N/A0.195% 4/24/2023Blodgett Wealth Advisors LLC29,660$92K0.1%N/A0.291% 4/14/2023BML Capital Management LLC411,398$1.28M1.1%N/A4.041% (Data available from 1/1/2016 forward) CARM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CARM shares? During the previous two years, 14 institutional investors and hedge funds held shares of Carisma Therapeutics. The most heavily invested institutionals were Trustees of The University of Pennsylvania ($3.67M), Vanguard Group Inc. ($3.59M), TPG GP A LLC ($1.28M), Barclays PLC ($539K), EA Series Trust ($355K), Geode Capital Management LLC ($254K), and American International Group Inc. ($113K).Learn more on Carisma Therapeutics' institutional investors. What percentage of Carisma Therapeutics' stock is owned by institutional investors? 44.27% of Carisma Therapeutics' stock is owned by institutional investors. Learn more on CARM's institutional investor holdings. Which institutional investors have been buying Carisma Therapeutics' stock? Of the 9 institutional investors that purchased Carisma Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Barclays PLC ($1.10M), Universal Beteiligungs und Servicegesellschaft mbH ($200K), Point72 Asia Singapore Pte. Ltd. ($52.01K), EA Series Trust ($40.43K), Renaissance Technologies LLC ($24.60K), Wexford Capital LP ($15K), and SG Americas Securities LLC ($13.65K). How much institutional buying is happening at Carisma Therapeutics? Institutional investors have bought a total of 1,390,192 shares in the last 24 months. This purchase volume represents approximately $1.24M in transactions. Which of Carisma Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Carisma Therapeutics stock in the last 24 months: TPG GP A LLC ($609.85K), Renaissance Technologies LLC ($86.64K), Geode Capital Management LLC ($24.22K), and Millennium Management LLC ($22.37K). How much institutional selling is happening at Carisma Therapeutics? Institutional investors have sold a total of 743,074 shares in the last 24 months. This volume of shares sold represents approximately $1.09M in transactions. Related Companies Evogene Major Shareholders Ikena Oncology Major Shareholders MediciNova Major Shareholders Invizyne Technologies Major Shareholders Adaptimmune Therapeutics Major Shareholders IGM Biosciences Major Shareholders PDS Biotechnology Major Shareholders Quantum Biopharma Major Shareholders Alto Neuroscience Major Shareholders Assertio Major Shareholders This page (NASDAQ:CARM) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
